Functional impairment of two novel mutations detected in lipoprotein-associated phospholipase A2 (Lp-PLA2) deficiency patients

[1]  M. Nagano,et al.  Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus Published, JLR Papers in Press, July 16, 2003. DOI 10.1194/jlr.D300021-JLR200 , 2003, Journal of Lipid Research.

[2]  C. Packard,et al.  Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease , 2003, Current opinion in lipidology.

[3]  M. Emi,et al.  Hypertriglyceridemia associated with amino acid variation Asn985Tyr of theRP1 gene , 2003, Journal of Human Genetics.

[4]  M. Emi,et al.  Interaction between the LDL-receptor gene bearing a novel mutation and a variant in the apolipoprotein A-II promoter: molecular study in a 1135-member familial hypercholesterolemia kindred , 2002, Journal of Human Genetics.

[5]  M. Emi,et al.  Head-to-head juxtaposition of Fas-associated phosphatase-1 (FAP-1) and c-Jun NH2-terminal kinase 3 (JNK3) genes: genomic structure and seven polymorphisms of the FAP-1 gene , 2002, Journal of Human Genetics.

[6]  Yusuke Nakamura,et al.  Gene-based SNP discovery as part of the Japanese Millennium Genome Project: identification of 190 562 genetic variations in the human genome , 2002, Journal of Human Genetics.

[7]  M. Emi,et al.  Clinical variant of Tangier disease in Japan: mutation of the ABCA1 gene in hypoalphalipoproteinemia with corneal lipidosis , 2002, Journal of Human Genetics.

[8]  A. Sekine,et al.  Identification of 779 genetic variations in eight genes encoding members of the ATP-binding cassette, subfamily C (ABCC/MRP/CFTR) , 2002, Journal of Human Genetics.

[9]  Yozo Ohnishi,et al.  [A high-throughput SNP typing system for genome-wide association studies]. , 2002, Gan to kagaku ryoho. Cancer & chemotherapy.

[10]  M. Emi,et al.  Eight novel mutations and functional impairments of the LDL receptor in familial hypercholesterolemia in the north of Japan , 2002, Journal of Human Genetics.

[11]  J. Sugatani,et al.  Association of a G994 →T Missense Mutation in the Plasma Platelet-Activating Factor Acetylhydrolase Gene With Risk of Abdominal Aortic Aneurysm in Japanese , 2002, Annals of surgery.

[12]  J. Manson,et al.  A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. , 2001, Journal of the American College of Cardiology.

[13]  D. Stengel,et al.  N-linked glycosylation of macrophage-derived PAF-AH is a major determinant of enzyme association with plasma HDL. , 2001, Journal of lipid research.

[14]  Yusuke Nakamura,et al.  A high-throughput SNP typing system for genome-wide association studies , 2001, Journal of Human Genetics.

[15]  T. Kodama,et al.  Evidence of Macrophage Foam Cell Formation by Very Low-Density Lipoprotein Receptor: Interferon-&ggr; Inhibition of Very Low-Density Lipoprotein Receptor Expression and Foam Cell Formation in Macrophages , 2001, Circulation.

[16]  H. Krumholz.  Lipoprotein-Associated Phospholipase A , 2001 .

[17]  L. Tjoelker,et al.  Platelet-activating factor acetylhydrolases in health and disease. , 2000, Biochimica et biophysica acta.

[18]  G. Lowe,et al.  Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. , 2000, The New England journal of medicine.

[19]  J. Sugatani,et al.  Plasma platelet-activating factor acetylhydrolase deficiency is associated with atherosclerotic occlusive disease in japan. , 2000, Journal of vascular surgery.

[20]  C. Packard,et al.  Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease , 2000 .

[21]  M. Yokota,et al.  Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. , 2000, Atherosclerosis.

[22]  T. Fukuda,et al.  Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma. , 1999, The Journal of clinical investigation.

[23]  M. Yokota,et al.  Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. , 1998, Metabolism: clinical and experimental.

[24]  T. Imaizumi,et al.  A mutation in plasma platelet-activating factor acetylhydrolase (Val279-->Phe) is a genetic risk factor for stroke. , 1997, Stroke.

[25]  G. Zimmerman,et al.  Platelet-activating Factor Acetylhydrolases* , 1997, The Journal of Biological Chemistry.

[26]  P. Macfarlane,et al.  West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials , 1996 .

[27]  G. Zimmerman,et al.  Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. , 1996, The Journal of clinical investigation.

[28]  G. Zimmerman,et al.  Mammalian platelet-activating factor acetylhydrolases. , 1996, Biochimica et biophysica acta.

[29]  G. Zimmerman,et al.  Anti-inflammatory properties of a platelet-activating factor acetylhydrolase , 1995, Nature.

[30]  F. Snyder,et al.  Platelet-activating factor and its analogs: metabolic pathways and related intracellular processes. , 1995, Biochimica et biophysica acta.

[31]  J. Berliner,et al.  Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. , 1995, The Journal of clinical investigation.

[32]  D. Stafforini,et al.  Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipids as substrates. , 1991, The Journal of biological chemistry.

[33]  G. Zimmerman,et al.  An oxidized derivative of phosphatidylcholine is a substrate for the platelet-activating factor acetylhydrolase from human plasma. , 1989, The Journal of biological chemistry.

[34]  U. Steinbrecher,et al.  Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase. , 1989, Journal of lipid research.

[35]  J. Sugatani,et al.  Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. , 1988, The Journal of clinical investigation.

[36]  D. Stafforini,et al.  Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. , 1987, The Journal of biological chemistry.

[37]  D. Stafforini,et al.  Human plasma platelet-activating factor acetylhydrolase. Purification and properties. , 1987, The Journal of biological chemistry.

[38]  A. Goldstein,et al.  Purification and properties , 1975 .

[39]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[40]  S. Yamashita,et al.  Two novel missense mutations in the CETP gene in Japanese hyperalphalipoproteinemic subjects: high-throughput assay by Invader ® assay , 2002 .

[41]  A. Sekine,et al.  Catalog of 77 single-nucleotide polymorphisms (SNPs) in the carbohydrate sulfotransferase 1 (CHST1) and carbohydrate sulfotransferase 3 (CHST3) genes , 2002, Journal of Human Genetics.

[42]  C. Packard,et al.  Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. , 2000, Atherosclerosis.

[43]  L. Tjoelker,et al.  Human plasma platelet-activating factor acetylhydrolase. , 1999, Methods in molecular biology.

[44]  G. Zimmerman,et al.  The platelet-activating factor acetylhydrolase from human plasma prevents oxidative modification of low-density lipoprotein. , 1992, Transactions of the Association of American Physicians.